info@biomedres.us   +1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Review ArticleOpen Access

Harnessing Vernon Smith’s Experimental Economics to Combat Antimicrobial Resistance in Sweden:A Simulation-Based Analysis Volume 59- Issue 5

Matteo Maria Cati*

  • University of Bologna 2 Scaravilli Square 40126 Bologna, Italy

Received: December 03, 2024; Published: December 05, 2024

*Corresponding author: Matteo Maria Cati, University of Bologna 2 Scaravilli Square 40126 Bologna, Italy

DOI: 10.26717/BJSTR.2024.59.009360

Abstract PDF

ABSTRACT

The relentless spread of antimicrobial resistance (AMR) poses a significant threat to global and Swedish public health, undermining the effectiveness of established antimicrobial therapies and increasing the burden of infectious diseases [1]. Drawing upon the extraordinary work of Nobel Laureate Vernon Smith in experimental economics [2], this study employs a comprehensive simulation-based analysis to evaluate the impact of targeted interventions aimed at curbing AMR in Sweden [3]. Utilizing Python to generate synthetic data sets, we simulate intricate market behaviors, supply-demand dynamics, and stakeholder responses that mirror the Swedish healthcare system’s complexity [4]. This approach allows for a nuanced exploration of how different interventions— ranging from stringent policy reforms to innovative behavioral nudges and extensive educational campaigns [5] - can influence AMR dynamics. Notably, this study integrates and expands upon critical findings from seminal works, leveraging the experimental frameworks established by Vernon Smith [1,6] to deliver novel insights into effective AMR management strategies.

Keywords: Experimental Economics; Antimicrobial Resistance; Simulation Modeling; Behavioral Nudges; Public Health Policy; Sweden

Introduction

Antimicrobial resistance (AMR) has rapidly emerged as one of the most serious public health concerns of our time, not only in Sweden but globally [7]. The ability of bacteria to adapt and resist the effects of antibiotics threatens the very cornerstone of modern medicine and has the potential to turn even the most routine medical procedures into high-risk operations [8]. Sweden, like many other countries, faces significant challenges in managing the rise of resistant infections, which are compounded by the complex dynamics of AMR’s evolution and spread within and across communities [9]. To address these challenges, this paper employs the pioneering experimental economic principles developed by Nobel Laureate Vernon Smith. His seminal work on using controlled laboratory settings to simulate market behaviors provides the methodological foundation for our approach [10]. By adapting Vernon Smith’s principles, notably from his research demonstrated in “An Experimental Study of Competitive Market Behavior” [11] and “Microeconomic Systems as an Experimental Science” [12], we are able to create a detailed and controlled simulation environment that mirrors the intricate dynamics of the Swedish healthcare system [13].

Methodology and Data Generation

1. Simulation Design: To address the complexities of antimicrobial resistance (AMR) and its impact on public health in Sweden, our study designs a series of controlled, simulation-based experiments reflecting various intervention scenarios [14]. Drawing on the experimental economic principles pioneered by Vernon Smith, these simulations are tailored to explore the potential effects of targeted interventions on AMR dynamics [15]. The simulations incorporate a variety of potential public health strategies, from stringent policy reforms to behavioral nudges and comprehensive educational campaigns, allowing us to examine their efficacy in a controlled yet realistic setting [16].
2. Data Generation using Python: To create a realistic model of the Swedish healthcare market and its interaction with AMR, we generate synthetic data sets using Python (see Appendix Figure 1) [17]. This programming environment is chosen for its robustness and flexibility in handling complex simulations [18]. The generated data encapsulates key variables that influence AMR, which are crucial for studying the impact of various interventions:
• Price Elasticity: Measures the responsiveness of antibiotic demand to changes in price. A lower price elasticity suggests that demand is less sensitive to price changes, which is important in scenarios where pricing strategies might be used to control antibiotic use [19].
• Demand: Represents the quantity of antibiotics demanded by the healthcare system, influenced by factors such as disease prevalence and public health policies [20].
• Supply: Indicates the availability of antibiotics, affected by manufacturing capacities, logistical capabilities, and regulatory decisions [21].
• Compliance: Reflects the adherence of healthcare providers and the public to AMR-related health guidelines and interventions [22].

The following table (Table 1) gives a snapshot of the theoretically generated data (first five raws and last five raws).

Table 1: Sample of Theoretically Generated Data (see Python Code in Appendix Figure 1).

biomedres-openaccess-journal-bjstr

Appendix Figure 1

biomedres-openaccess-journal-bjstr

Explanation of the Generated Data

This dataset contains 1,000 rows, where each row represents a simulated data point. The columns correspond to four key variables influencing antimicrobial resistance (AMR) and healthcare dynamics in the Swedish context. Here’s a detailed explanation of each variable:

Price Elasticity

Description: Measures how sensitive the demand for antibiotics is to price changes.
Distribution: Generated using a normal distribution with a mean of -1.2 and a standard deviation of 0.3.
Interpretation: Negative values indicate that as prices increase, demand decreases (elastic behavior). A steeper slope implies higher sensitivity.

Demand

• Description: Represents the quantity of antibiotics demanded in the healthcare system.
• Distribution: Generated using a normal distribution with a mean of 1,000 and a standard deviation of 200.
• Interpretation: Higher values suggest increased antibiotic usage, possibly due to outbreaks or higher disease prevalence. Lower values indicate reduced consumption, potentially from effective public health interventions.

Supply

• Description: Reflects the availability of antibiotics in the healthcare system.
• Distribution: Generated using a uniform distribution between 700 and 1,300.
• Interpretation: Values within this range simulate realistic supply constraints and production levels in the market.

Compliance

• Description: Indicates the level of adherence to guidelines related to antibiotic usage.
• Distribution: Generated using a uniform distribution between 0.7 and 1.0.
• Interpretation: Values closer to 1.0 indicate higher adherence to prescribing guidelines and best practices, while values closer to 0.7 suggest moderate compliance.

Table 2 shows a Summary of Generated Data.

Table 2: Summary of Generated Data (see Appendix Figure 1 for the Python Code).

biomedres-openaccess-journal-bjstr

Explanation of the Summary Statistics

The summary statistics provide an overview of the key characteristics of the generated data, helping to understand the distribution and variability of each variable. Here’s a detailed explanation of the statistics for each variable:

Price Elasticity

• Count: 1,000 observations.
• Mean: -1.194, indicating a moderately elastic demand where a change in price significantly impacts the quantity demanded.
• Standard Deviation (std): 0.294, reflecting some variability in price sensitivity among scenarios.
• Minimum (min): -2.172, showing extreme cases where demand is highly sensitive to price.
• 25th Percentile (25%): -1.394, meaning 25% of observations are less elastic than this value.
• Median (50%): Approximately -1.2, a common value representing typical price sensitivity in the simulated scenarios.
• 75th Percentile (75%): -1.006, indicating less sensitivity among the top 25% of observations.
• Maximum (max): -0.044, where demand shows minimal price elasticity.

Demand

• Count: 1,000 observations.
• Mean: 1,014 units, representing the average demand level.
• Standard Deviation (std): 199.49, showing considerable
variation, likely reflecting different demand scenarios (e.g., seasonal surges or reduced usage).
• Minimum (min): 411.92, indicating very low demand, perhaps in low-incidence periods or due to interventions.
• 25th Percentile (25%): 878.75, the lower quartile of demand.
• Median (50%): 1,000 units, the most common demand level.
• 75th Percentile (75%): 1,145.78, suggesting higher demand scenarios in the upper quartile.
• Maximum (max): 1,638.62, indicating peak demand likely driven by an outbreak or crisis.

Supply

• Count: 1,000 observations.
• Mean: 998.11 units, reflecting an average supply close to the demand mean.
• Standard Deviation (std): 174.19, showing moderate variability in supply levels.
• Minimum (min): 700.01, highlighting scenarios with constrained supply.
• 25th Percentile (25%): 848.50, representing the lower range of supply levels.
• Median (50%): 1,000 units, aligning closely with the demand median.
• 75th Percentile (75%): 1,148.94, indicating a robust supply in upper quartile scenarios.
• Maximum (max): 1,299.34, demonstrating peak supply availability.

Compliance

• Count: 1,000 observations.
• Mean: 0.845 (84.5%), reflecting high average compliance with AMR-related guidelines.
• Standard Deviation (std): 0.085, indicating relatively small variation in compliance rates.
• Minimum (min): 0.7 (70%), showing moderate compliance in the least adherent scenarios.
• 25th Percentile (25%): 0.771 (77.1%), representing the lower quartile of compliance.
• Median (50%): 0.846 (84.6%), a typical compliance rate.
• 75th Percentile (75%): 0.917 (91.7%), suggesting high adherence among the upper quartile.
• Maximum (max): 0.999 (99.9%), almost perfect compliance.

Key Insights from the Summary

• Price Elasticity: The distribution shows moderate variability, with most values indicating significant sensitivity to price changes. This supports the use of pricing strategies in interventions.

• Demand: The wide spread indicates the potential impact of external factors like public health crises or seasonal trends.

• Supply: The close alignment of the mean supply and demand highlights an attempt to balance production with needs, though variability suggests potential mismatches.

• Compliance: High average compliance rates reflect strong adherence to guidelines, but there is room for improvement in scenarios with lower adherence.

This comprehensive summary helps identify trends, anomalies, and potential focus areas for intervention strategies to manage AMR effectively.

Simulation Results and Analysis

Following the summary statistics, the focus transitions to analyzing the simulated data to evaluate the effectiveness of various AMR intervention strategies. This section presents both quantitative and visual insights, drawing connections between the theoretical data and real-world implications for Sweden’s healthcare system.

Simulation Results

Price Elasticity and Demand Analysis:

• Observations: A strong correlation is observed between price elasticity and demand. During scenarios of high elasticity (closer to -1.0), demand is significantly influenced by price changes, whereas low elasticity scenarios (e.g., -2.0) show that price adjustments have minimal effects.
• Implications: Pricing strategies, such as imposing higher costs on non-essential antibiotics, could reduce overuse, particularly in contexts where demand is highly elastic.

Supply and Compliance Trends:

• Observations: Fluctuations in supply directly impact compliance rates. In scenarios where supply constraints are severe (e.g., values close to 700 units), compliance dips below 80%, likely due to healthcare providers compromising on best practices to manage shortages.
• Implications: Strengthening supply chains and ensuring consistent availability of antibiotics are critical for maintaining high compliance rates.

Demand-Supply Balance and AMR Management:

• Observations: Imbalances between demand and supply contribute to significant pressure on healthcare systems. Scenarios with demand outstripping supply by 30% or more correlate with increased risks of misuse and the potential acceleration of AMR (Figure 1).

• Implications: Policymakers should consider demand forecasting models and buffer stock strategies to address seasonal spikes or unexpected surges in demand.

Figure 1

biomedres-openaccess-journal-bjstr

Visual Representation of Key Variables

The following four plots summarize how the key variables evolve over time (see Appendix Figure 2 fothe Pyhton codes):

Appendix Figure 2

biomedres-openaccess-journal-bjstr

Price Elasticity Over Time

• Insights: This plot shows a steady fluctuation in price elasticity values, reflecting varying levels of demand sensitivity. Peaks indicate periods of increased consumer responsiveness to pricing interventions, ideal for implementing costbased controls.

Demand and Supply Over Time

• Insights: These variables show cyclical trends, with demand occasionally exceeding supply. Such instances highlight the necessity for adaptive supply chain policies and contingency planning for periods of heightened demand.

Compliance Over Time

• Insights: Compliance rates show variability but generally trend above 80%. Targeted interventions, such as provider training programs and public education campaigns, could drive this closer to 100%.

Policy Implications and Recommendations

1. Behavioral Interventions

• Key Strategy: Leverage Vernon Smith’s experimental economic insights to design behavioral nudges targeting healthcare providers. For example:
• Implement decision-support systems that prompt optimal prescribing behavior.
• Utilize feedback loops where providers receive monthly compliance reports compared to peers.

2. Economic Incentives

• Key Strategy: Use pricing strategies to discourage the overuse of antibiotics, particularly in scenarios with high elasticity. Subsidizing critical antibiotics could ensure affordability while maintaining stringent oversight.

3. Supply Chain Improvements

• Key Strategy: Develop robust supply chain frameworks to manage unexpected demand surges. Encourage regional collaboration among Nordic countries to create a shared stockpile of critical antibiotics.

4. Public Health Campaigns

• Key Strategy: Increase awareness about AMR through sustained educational initiatives.

Focus on reducing unnecessary demand and promoting adherence to treatment regimens.

Conclusion and Future Research

This simulation-based study underscores the value of integrating experimental economic principles with healthcare policy design to combat AMR effectively [23]. By modeling the Swedish healthcare system’s dynamics, this research highlights actionable strategies, such as pricing interventions, supply chain resilience, and behavioral nudges, that can significantly reduce AMR prevalence [24]. Future research directions include expanding simulations to include real-world data from Sweden and other Nordic countries to enhance accuracy, investigating the long-term economic impact of AMR interventions using multi-year projections, and exploring the role of emerging technologies, such as AI and blockchain, in improving compliance and supply chain management [25-29].

Future Research Directions

• Expand simulations to include real-world data from Sweden and other Nordic countries to enhance accuracy.
• Investigate the long-term economic impact of AMR interventions using multi-year projections.
• Explore the role of emerging technologies, such as AI and blockchain, in improving compliance and supply chain management [30-40].

Acknowledgments

I would like to express my deepest gratitude to Nobel Prize of Economics Professor Vernon L. Smith, whose groundbreaking contributions to experimental economics have profoundly shaped the foundation of this research. His extraordinary work, particularly in understanding market behaviors through controlled experiments, provided the methodological inspiration for this study. Moreover, our email exchange has been a source of immense encouragement and intellectual stimulation. Professor Smith’s insights and generous engagement have not only guided this exploration into antimicrobial resistance management but continue to inspire my work in pushing the boundaries of applied economics in healthcare policy. His pioneering spirit and scholarly excellence are a beacon for researchers worldwide, and it is a great honor to build upon his legacy in this study.

References

  1. Golding S E, Ogden J, Higgins H M (2019) Shared goals, different barriers: a qualitative study of uk veterinarians' and farmers' beliefs about antimicrobial resistance and stewardship. Frontiers in Veterinary Science 6: 132.
  2. Smith V L (1962) An Experimental Study of Competitive Market Behavior. Journal of Political Economy 70(2): 111-137.
  3. Leal, John Conly, Elizabeth Ann Henderson, Braden J Manns (2017) How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations. Antimicrobial resistance and infection control 6: 53.
  4. Coyne, Carolyn Benigno, Vo Ngan Giang, Luu Quynh Huong, Wantanee Kalprividh, et al. (2020) Exploring the Socioeconomic Importance of Antimicrobial Use in the SmallScale Pig Sector in Vietnam. Antibiotics 9(6): 299.
  5. Kashef, Gholamreza Esmaeeli Djavid, Sahba Shahbazi (2010) Antimicrobial susceptibility patterns of community-acquired uropathogens in Tehran, Iran. The journal of infection in developing countries 4(4): 202-206.
  6. Smith V L (1976) Experimental Economics: Induced Value Theory. The American Economic Review 66(2): 274-279.
  7. (2023) Evaluation of Restricted Antimicrobial Utilization in a Tertiary Care Hospital. International journal for multidisciplinary research.
  8. Lewis (2010) The Gonococcus fights back: is this time a knock out? Sexually transmitted infections 86(6): 415-421.
  9. Espona, Daniel Echeverria-Esnal, Sergi Hernandez, Alexander Almendral (2021) Impact of Generic Entry on Hospital Antimicrobial Use: A Retrospective Quasi-Experimental Interrupted Time Series Analysis. Antibiotics 10(10): 1149.
  10. Smith V L (1989) Theory, Experiment and Economics. Journal of Economic Perspectives 3(1): 151-169.
  11. Wang Y, Xu X, Zhu B, Lyu N, Liu Y, et al. (2023) Genomic analysis of almost 8,000 Salmonella genomes reveals drivers and landscape of antimicrobial resistance in China. Microbiol Spectr 11(6): e0208023.
  12. Andreoni J, Harbaugh W T, Vesterlund L (2003) The carrot or the stick: rewards, punishments, and cooperation. American Economic Review 93(3): 893-902.
  13. Queenan Barbara Häsler, Jonathan Rushton (2016) A One Health approach to antimicrobial resistance surveillance: is there a business case for it?. International journal of antimicrobial agents 48(4): 422-427.
  14. Innes, Pranay R Randad, Anton Korinek, Meghan F Davis, Lance B Price, et al. (2019) External Societal Costs of Antimicrobial Resistance in Humans Attributable to Antimicrobial Use in Livestock. 41(1).
  15. Gordon, Maria Gheorghe, Cale Harrison, Ryan Miller, James Dennis, et al. (2023) Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study. Pharmacoeconomics 42(3): 329-341.
  16. Gordon, Oliver Darlington, Phil McEwan, Matthew Lumley, Amer Taie, et al. (2020) Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model. Pharmacoeconomics 38(8): 857-869.
  17. Kumar, Anu Sharma, Yasmeen M, Parwez (2021) A review on Antibiotic Policy and Antimicrobial Stewardship Program (AMSP) – Need of the hour. International journal of research in pharmaceutical sciences 12(2): 1233-1237.
  18. Belkina, Abdullah Al Warafi, Elhassan Hussein Eltom, Nigora Tadjieva, Ales Kubena, et al. (2014) Antibiotic use and knowledge in the community of Yemen, Saudi Arabia, and Uzbekistan. The journal of infection in developing countries 8(4): 424-429.
  19. Dadgostar (2019) Antimicrobial Resistance: Implications and Costs. Infection and drug resistance 12: 3903-3910.
  20. Pietro, Simone Filardo, Rosa Sessa (2024) Editorial for the Special Issue Antibacterial Activity of Drug-Resistant Strains. International journal of molecular sciences 25(3): 1878.
  21. Coyne, Riana Arief, Carolyn Benigno, Vo Ngan Giang, Luu Quynh Huong, et al. (2019) Characterizing Antimicrobial Use in the Livestock Sector in Three South East Asian Countries (Indonesia, Thailand, and Vietnam). Antibiotics 8(1): 33.
  22. Ahmed, Abdul Haseeb, Azmi Ahmed Hassali, Amer H Khan (2021) Antimicrobial Stewardship Interventions: Narrative Review. Journal of pharmaceutical research international 33(23B): 62-71.
  23. Boeckel, Charles Brower, Marius Gilbert, Bryan T Grenfell, Simon A Levin, et al. Global trends in antimicrobial use in food animals. Proceedings of the national academy of sciences 112(18): 5649-5654.
  24. Cole, G Spiteri, S A Chisholm, S Hoffmann, C A Ison, et al. (2014) Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe. Eurosurveillance 19(45): 20955.
  25. Cassini, Liselotte Diaz Högberg, Diamantis Plachouras, Annalisa Quattrocchi, Ana Hoxha, et al. (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a populationlevel modelling analysis. The lancet infectious diseases 19(1): 56-66.
  26. Ananthakrishnan, Chris Painter, Yot Teerawattananon (2021) A protocol for a systematic literature review of economic evaluation studies of interventions to address antimicrobial resistance Systematic reviews 10(1): 242.
  27. Holmes, Hughes (2019) Challenges for Economic Evaluation of Health Care Strategies to Contain Antimicrobial Resistance Antibiotics 8(4): 166.
  28. Khaledi, Monika Schniederjans, Sarah Pohl, Roman Rainer, Ulrich Bodenhofer, et al. (2016) Transcriptome Profiling of Antimicrobial Resistance in Pseudomonas aeruginosa Antimicrobial agents and chemotherapy 60(8): 4722-4733.
  29. Hong J, Sylvester W, Alhassan A, Sharma B, Amadi V, et al. (2024) Retrospective analysis of antimicrobial susceptibility pattern of pseudomonas aeruginosa from clinical samples of dogs in grenada, west indies. Indian Journal of Animal Research.
  30. Gao F, Huang Z, Xiong Z, Zheng H, Deng Q (2023) Prevalence, serotype, and antimicrobial resistance profiles of children infected with salmonella in guangzhou, southern china, 2016–2021. Frontiers in Pediatrics 15(11):
  31. Ducrot C, Guénin M, Hémonic A, Rousset N, Carré Y, et al. (2022) Towards a better use of antimicrobials on farms: insights from a participatory approach in the french pig and poultry sectors. Antibiotics 11(10):1370.
  32. Espona M, Echeverría-Esnal D, Hernández S, Almendral A, Gómez-Zorrilla S, et al. (2021) Impact of generic entry on hospital antimicrobial use: a retrospective quasi-experimental interrupted time series analysis. Antibiotics 10(10): 1149.
  33. Ducrot C, Guénin M, Hémonic A, Rousset N, Carré Y, et al. (2022) Towards a better use of antimicrobials on farms: insights from a participatory approach in the french pig and poultry sectors. Antibiotics 11(10):1370.
  34. Martínez-Agüero S, Mora-Jiménez I, Lérida-García J, Álvarez-Rodríguez J, SogueroRuíz C, et al. (2019) Machine learning techniques to identify antimicrobial resistance in the intensive care unit. Entropy 21(6): 603
  35. Hopman N, Hulscher M, Graveland H, Speksnijder D C, Wagenaar J A, et al. (2018) Factors influencing antimicrobial prescribing by dutch companion animal veterinarians: a qualitative study. Preventive Veterinary Medicine 158: 106-113.
  36. Coyne L, Latham S M, Williams N, Dawson S, Donald I, et al. (2016) Understanding the culture of antimicrobial prescribing in agriculture: a qualitative study of uk pig veterinary surgeons. Journal of Antimicrobial Chemotherapy 71(11): 3300-3312.
  37. Yasein N, Shroukh W, Barghouti F, Hassanin O M, Yousef H Y, et al. (2021) The potential counter effect of covid-19 outbreak on an antimicrobialagents prescribing educational intervention. The Journal of Infection in Developing Countries 15(11): 1653-1660.
  38. Jorge, Martín Pérez Pérez, Gael Pérez Rodríguez, Florentino Fdez Riverola, Maria Olívia Pereira, et al. (2016) Construction of antimicrobial peptide-drug combination networks from scientific literature based on a semi-automated curation workflow. Database.
  39. Naylor, Rifat Atun, Nina Zhu, Kavian Kulasabanathan, Sachin Silva, et al. (2018) Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrobial resistance and infection control 7: 58.
  40. Changkaew, Fuangfa Utrarachkij, Kanokrat Siripanichgon, Chie Nakajima, Orasa Suthienkul, et al. (2014) Characterization of Antibiotic Resistance in Escherichia coli Isolated from Shrimps and Their Environment. Journal of food protection 77(8): 1394-1401.